Hikma Pharmaceutical Partnership With Biocryst For Flu Product
January 11 2010 - 7:38AM
Dow Jones News
Hikma Pharmaceuticals PLC (HIK.LN), a speciality pharmaceutical
company, said Monday that it has signed an exclusive agreement to
represent BioCryst in respect of its anti-viral product peramivir
for pandemic flu treatment stockpiling opportunities with
governments in the Middle East and North Africa region.
-By London Bureau, Dow Jones Newswires; Contact Ian Walker; +44 (0)20 7842 9296; ian.walker@dowjones.com
Hikma Pharmaceuticals (PK) (USOTC:HKMPY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Hikma Pharmaceuticals (PK) (USOTC:HKMPY)
Historical Stock Chart
From Sep 2023 to Sep 2024